Home » Knowledge Center » Pharmaron Symposium in DMPK & Biology 
Banner for the "1st Pharmaron Symposium in DMPK & Biology," held on May 30, 2015, in Pharmaron, Beijing, China. The background features images of DNA strands and a mountainous landscape, highlighting the focus on preclinical ADME studies.

Pharmaron Symposium in DMPK & Biology

May 30, 2015 l Beijing Headquarters

  • Prof. Jufeng Wang, Director, National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, China: Stem Cell Innovates New Drug Development 
  • Prof. Yue Ma, Institute of Biophysics, Chinese Academy of Sciences, China: Human PSC Derived Cardiomyocytes and Their Applications in Cardio Toxicity Analysis
  • Dr. Vincent Jaquet, University of Geneva, Switzerland: NOX Inhibitors: A Tale of Their Discovery, Characterizations and Applications for Therapy in Human Diseases
  • Dr. Barry C. Jones, Senior Principal Scientist, DMPK, AstraZeneca, UK: Prediction of Drug-Drug Interactions: Interplay of in vitro and in silico DMPK
  • Dr. Jonathan Huw Connick, Executive Director, Research Sciences, Merck, US and MSD, China: A Glimpse into the Drug Discovery Process – The Orexin Receptor Antagonist Program for Insomnia
  • Dr. David Evans, Vice President, Head of Global Pharmacokinetics, Dynamics & Metabolism, Janssen R&D, Johnson & Johnson, US: Mechanism Based Drug Disposition: Building Quality into Our Product Pipeline